Understanding Addiction — The Science, Explained

By SoCal Addiction Centers Editorial Team | Last reviewed: | 18 min read Clinically Reviewed

Key Takeaways

  • Addiction is a medical condition, clinically called substance use disorder (SUD). The DSM-5-TR defines SUD through 11 diagnostic criteria, with severity classified as mild (2–3 criteria), moderate (4–5 criteria), or severe (6+ criteria). It is a diagnosis made by licensed clinicians against standardized criteria, not a moral judgment.
  • The brain-disease model of addiction — adopted by NIDA, NIAAA, ASAM, and SAMHSA — frames SUD as involving measurable changes to the brain’s reward, learning, motivation, and executive-function systems. The framing is not “the brain made them do it”; it is “these are the systems where treatment intervenes.”
  • Heritability is substantial. Twin and family studies estimate genetic contribution to SUD risk at roughly 50%, with the remaining variance attributable to environmental factors, developmental timing of substance exposure, adverse experiences, and individual characteristics. Heritability varies somewhat by substance; alcohol and opioid heritability estimates sit in that range.
  • Adolescent brain vulnerability matters. The prefrontal cortex — the brain region governing impulse control, risk evaluation, and executive function — continues maturation until approximately age 25. Substance use during adolescence interacts with developing neural systems in ways that raise SUD risk across the lifespan.
  • Dual diagnosis is the norm. Approximately 50% of people with SUD have a co-occurring mental health condition. Treating one while ignoring the other produces worse outcomes than integrated treatment. See our dual diagnosis pillar.
  • Treatment works. Evidence from decades of research supports FDA-approved medications (for opioid, alcohol, nicotine) combined with behavioral treatment (CBT, motivational interviewing, contingency management, family therapy). Treatment outcomes improve with longer engagement.
  • Recovery is a process, not an endpoint. SAMHSA’s Recovery Oriented System of Care (ROSC) framework emphasizes long-term engagement across continuing care, peer support, and social determinants — not a single “cure.”

Understanding addiction — starting from the science

Addiction, clinically called substance use disorder (SUD), is a medical condition affecting approximately 10% of U.S. adults at some point in their lifetime per published epidemiological data. It involves measurable changes to brain systems governing reward, learning, motivation, and executive function. It has a roughly 50% heritable component per twin-and-family-study estimates. It is diagnosed against 11 specific criteria in the DSM-5-TR with severity tiers. It responds to evidence-based treatment at rates comparable to other chronic medical conditions like diabetes, hypertension, and asthma.

This page explains what addiction is clinically, the neurobiology that underlies it, the genetic and environmental factors that shape individual risk, the consequences of stigma for treatment access, and what “recovery” actually means in the Recovery Oriented System of Care (ROSC) framework adopted by SAMHSA. The page is written for people trying to understand a family member’s or their own situation, for clinicians looking for a clean lay-accessible framework, and for anyone approaching SUD as a medical rather than moral question.

We accept no referral fees. The framing throughout is the established consensus of NIDA, NIAAA, SAMHSA, and ASAM — not editorial advocacy.

What SUD is — DSM-5-TR diagnostic criteria

The DSM-5-TR — the American Psychiatric Association’s diagnostic manual, text-revised in 2022 — defines substance use disorder across 11 diagnostic criteria, grouped into four clusters:

Impaired control (4 criteria):

  1. Using more than intended or for longer than intended
  2. Unsuccessful efforts or persistent desire to cut down
  3. Spending significant time obtaining, using, or recovering from use
  4. Craving — strong desire to use

Social impairment (3 criteria): 5. Failure to fulfill major role obligations (work, school, home) due to use 6. Continued use despite persistent social/interpersonal problems caused by use 7. Giving up or reducing important social, occupational, or recreational activities due to use

Risky use (2 criteria): 8. Using in physically hazardous situations 9. Continued use despite knowing it causes or worsens physical/psychological problems

Pharmacological criteria (2 criteria): 10. Tolerance — needing more to achieve the same effect, or reduced effect at same dose 11. Withdrawal — characteristic withdrawal syndrome, or using to avoid/relieve withdrawal

Severity is determined by the number of criteria met within a 12-month window:

  • Mild SUD: 2–3 criteria
  • Moderate SUD: 4–5 criteria
  • Severe SUD: 6 or more criteria

DSM-5-TR structures SUD diagnoses for specific substances: alcohol use disorder, opioid use disorder, stimulant use disorder, cannabis use disorder, sedative/hypnotic/anxiolytic use disorder (includes benzodiazepines), tobacco use disorder, and others. The 11-criteria framework applies across substance types with some substance-specific adaptations.

The brain-disease model — what it does and doesn’t say

The “brain disease” framing of addiction has been adopted by major federal research and treatment authorities — NIDA, NIAAA, ASAM, and SAMHSA — because decades of neuroscience research have documented measurable changes to specific brain systems in individuals with SUD.

What the brain-disease model says:

  1. Substance use produces measurable changes in brain systems governing reward (mesolimbic dopamine pathway), learning (ventral striatum and hippocampus), motivation (prefrontal cortex and amygdala), and executive function (prefrontal cortex)
  2. These changes persist beyond active substance use, producing ongoing vulnerability to craving, relapse, and return-to-use patterns
  3. Treatment intervenes on these brain systems — MAT works by modulating receptor systems, behavioral treatment strengthens prefrontal cognitive control over craving responses
  4. SUD is chronic and relapsing like other chronic medical conditions — diabetes, hypertension, asthma — that require long-term management

What the brain-disease model does NOT say:

  • It does not say “the brain made them do it” in a way that removes patient agency
  • It does not say recovery is impossible — in fact, it directly supports evidence-based treatment efficacy
  • It does not replace social, psychological, or spiritual dimensions of recovery — it complements them

Critiques of the brain-disease model exist and are worth acknowledging. Some researchers and clinicians argue the model over-medicalizes what is also a social, psychological, and experiential phenomenon. The SAMHSA consensus integrates brain-science framing with social-determinants framing rather than choosing one exclusively.

For our editorial purposes: we present the brain-disease model as the mainstream consensus while recognizing SUD is also shaped by social, economic, cultural, and individual factors that purely biological framing doesn’t capture.

The neurobiology — what’s actually happening

For readers who want the specifics, here is what neuroscience research has established about the brain systems involved in SUD.

The reward and learning systems

Dopamine signaling in the mesolimbic pathway — the circuit connecting the ventral tegmental area (VTA) to the nucleus accumbens and prefrontal cortex — is the primary reward-signaling system of the brain. Natural rewards (food, water, sex, social connection, achievement) produce dopamine signaling. Addictive substances — alcohol, opioids, cocaine, methamphetamine, nicotine, cannabis — produce dopamine signaling that is typically larger and more rapid than natural rewards.

Repeated substance-induced dopamine signaling produces neuroadaptations:

  • Downregulation of dopamine receptors — the system becomes less responsive to both substance-induced signaling and natural rewards
  • Strengthened association learning — cues associated with substance use (places, people, emotional states) become triggering
  • Reduced sensitivity to natural rewards — things that produced pleasure before substance use become less rewarding (“anhedonia”)

The executive function and decision-making systems

The prefrontal cortex (PFC) governs impulse control, risk evaluation, long-term planning, and executive decision-making. Chronic substance use is associated with reduced PFC function and volume — observable on neuroimaging in SUD populations. The consequences:

  • Reduced capacity to “override” craving responses despite intent to abstain
  • Difficulty with delayed gratification and long-term planning
  • Impaired decision-making under stress

PFC maturation completes around age 25, making adolescent substance use particularly consequential for long-term PFC function.

The stress and anxiety systems

The extended amygdala and HPA axis mediate stress responses. Chronic substance use dysregulates stress signaling — producing elevated baseline stress and anxiety during withdrawal and early recovery. Post-acute withdrawal syndrome (PAWS) reflects this dysregulation; the system normalizes over weeks to months but creates vulnerability during the normalization period.

Implications for treatment

Evidence-based treatment intervenes on these systems:

  • MAT (buprenorphine, methadone, naltrexone, acamprosate) directly modulates receptor systems to reduce craving and block reinforcement
  • Behavioral treatment (CBT, MI, contingency management) strengthens PFC cognitive control over craving responses through learning-based interventions
  • Peer support and social engagement rebuild natural-reward signaling capacity
  • Time — the neurobiology progressively normalizes with sustained abstinence and treatment engagement, though some changes may persist

Genetics and environment — the roughly 50/50 frame

Twin and family studies estimate the heritable contribution to SUD risk at approximately 50% — meaning half of individual variation in SUD risk is explained by genetic factors, half by environmental and experiential factors. This is an average across studies and substances; specific substance heritability estimates sit in the 40–70% range depending on methodology.

What “50% heritability” means:

What the remaining 50% (environmental contribution) includes:

  • Age of first substance use — earlier use associated with higher SUD risk
  • Adverse Childhood Experiences (ACEs) — trauma, abuse, neglect, household dysfunction in childhood substantially elevate SUD risk
  • Peer substance use — particularly during adolescence
  • Socioeconomic factors — poverty, housing instability, employment insecurity
  • Substance availability — geographic and cultural context
  • Mental health comorbidity — SUD self-medication of underlying conditions
  • Chronic pain — opioid SUD particularly

The additive interaction: high-genetic-risk individuals with protective environmental factors (stable households, delayed substance initiation, strong social support) have lower observed SUD rates than high-genetic-risk individuals with unfavorable environmental factors. Genetic risk is not destiny.

Adolescent vulnerability — the developmental window

The prefrontal cortex continues maturation until approximately age 25. During this developmental window, substance use interacts with developing neural systems in specific ways:

  • Neuroplasticity is higher, making substance-induced adaptations more durable
  • Executive function is still developing, making self-regulation against substance use harder
  • Social context weighs heavily in decision-making — peer influence is operationally larger during adolescence
  • Mental health conditions often emerge during adolescence and early adulthood, creating dual-diagnosis initiation patterns

Epidemiologically, substance use initiation before age 15 is associated with substantially higher lifetime SUD risk than initiation after age 21 — for alcohol, cannabis, and opioids particularly. This is one of the strongest findings in addiction epidemiology.

Prevention implications: delayed substance initiation, early intervention for adolescent use, and supportive environments during the adolescent-through-mid-20s window reduce population-level SUD incidence. Adolescent SUD treatment (where indicated) is distinct from adult treatment — developmental-appropriateness matters clinically.

Co-occurring mental health — dual diagnosis

Approximately 50% of people with SUD have a co-occurring mental health condition during their lifetime. Common patterns:

  • Depression + alcohol use disorder
  • PTSD or trauma + opioid use disorder
  • Anxiety disorders + benzodiazepine use disorder
  • Bipolar disorder + multiple SUDs
  • ADHD + stimulant use disorder (self-medication pattern)
  • Schizophrenia-spectrum disorders + cannabis or other SUDs

The interaction is bidirectional:

  • Mental health conditions drive substance self-medication
  • Substance use exacerbates mental health symptoms
  • Effective treatment addresses both simultaneously (integrated treatment)

See our dual diagnosis pillar for integrated-treatment framework.

Stigma — the treatment barrier

Despite decades of scientific consensus about addiction as a medical condition, substantial public stigma persists. Consequences for treatment access:

Internalized stigma — individuals with SUD often experience shame and self-blame that delays treatment-seeking. Family members similarly experience stigma-related reluctance to discuss SUD openly or connect to treatment resources.

Healthcare stigma — medical settings outside addiction specialty occasionally express stigma or provide reduced-quality care to SUD patients. This contributes to avoidance of primary care and ED use for acute complications rather than preventive care.

Employment stigma — fear of professional consequences from disclosed SUD history. ADA protections exist but are imperfectly enforced; family support and confidentiality considerations affect treatment choice.

Legal stigma — particularly for patients with prior legal consequences of substance use, concerns about disclosure affect treatment-seeking.

California-specific stigma context: California has historically been more progressive than most states on addiction as a medical rather than criminal issue. The 2020 legislative and policy environment through CalAIM integration reflects continued movement toward treating SUD as a healthcare condition. The 2024 Prop 36 voter approval, however, signaled some reversal of this trajectory at the state level — producing a more complex current context around stigma and criminalization.

The medical vs moral framing — a historical arc

Public understanding of addiction has shifted substantially across the 20th and 21st centuries. The current medical framing reflects decades of scientific research and policy evolution, but the moral framing persists in parts of public discourse and creates ongoing challenges for treatment access.

Pre-20th century: addiction was variably framed as moral failing, disease, or habitual behavior depending on era and culture. Alcohol use disorder received earliest medical framing through the 19th-century “inebriety” medical movement. Opioid use disorder was similarly medicalized initially — morphine and opium dependence among Civil War veterans and medical patients drove some of the earliest treatment-system development.

Early 20th century prohibition and criminalization: the 1914 Harrison Narcotics Act and 1919 Prohibition reflected a shift toward criminalization of substance use. Medical providers who prescribed morphine for dependence were prosecuted; addiction was increasingly framed as moral and criminal rather than medical.

Mid-20th century reframing: the 1950s-60s saw renewed interest in addiction as medical condition. The American Medical Association formally classified alcoholism as a disease in 1956. Alcoholics Anonymous, founded 1935, had always used disease framing even as broader society did not. Opioid treatment programs emerged in the 1960s.

Late 20th century neuroscience: the 1970s-90s saw rapid growth in addiction neuroscience research. Dopamine reward system research, brain-imaging research, and receptor pharmacology research established the biological basis of SUD. NIDA was founded in 1974; NIAAA in 1970.

21st century integration: the DSM-IV and DSM-5 progressively medicalized addiction diagnoses. Federal parity law (2008 MHPAEA and ACA provisions) required insurance coverage parity. ASAM Criteria became the clinical placement standard. MAT for OUD, AUD, and nicotine use disorder became mainstream.

Current arc: the scientific consensus is clearly medical. The policy and cultural environment shows partial adoption — California’s behavioral health system broadly operates on medical framing; criminal justice system engagement with substance use continues to include significant moral/criminal framing (drug courts, Prop 36 of 2024, Alexandra’s Law). The practical result is individuals with SUD encountering different framings in different institutional contexts.

The moral framing has real consequences:

  • Self-blame and delayed treatment-seeking — patients who internalize moral framing often delay help-seeking for years
  • Family shame — families operating in moral framing may be reluctant to support treatment engagement or to acknowledge SUD publicly
  • Employment concerns — SUD disclosure remains stigmatized in many workplaces despite ADA protections
  • Healthcare stigma — some medical settings continue to treat SUD patients differently, including in pain-management access for patients with OUD history

The medical framing is supported by decades of neuroscience and clinical outcome research. It is also an editorial posture — our editorial position explicitly favors the medical framing for the practical reason that it correlates with better treatment-seeking, treatment engagement, and sustained recovery outcomes.

Family dynamics in SUD

Addiction affects families, not only individuals. The family-system framework of SUD has substantial clinical grounding and informs both treatment planning and recovery support.

Common family patterns in SUD:

  • Codependency — a partner, parent, or child organizing their own functioning around the person with SUD, often at cost to their own wellbeing
  • Enabling — behaviors that inadvertently reduce the natural consequences of substance use, which can delay the patient’s engagement with treatment
  • Family roles — scapegoat, hero, lost child, mascot — children of SUD parents often develop specific adaptation patterns
  • Secondary trauma — family members of SUD patients frequently develop trauma responses that warrant clinical attention
  • Intergenerational transmission — SUD runs in families through combined genetic and environmental pathways; children of SUD parents have elevated SUD risk even when raised in non-using environments

Evidence-based family involvement in treatment:

  • Family therapy — Multidimensional Family Therapy (MDFT) and Functional Family Therapy (FFT) for adolescent SUD; Behavioral Couples Therapy (BCT) for adult patients in relationships
  • Family psychoeducation — teaching family members about SUD, treatment, and supportive engagement
  • Family peer support — Al-Anon, Nar-Anon, CRAFT (Community Reinforcement and Family Training) for family members

What family members can do:

  • Attend therapy or psychoeducation of their own — family members often benefit from their own clinical engagement
  • Learn the CRAFT framework — an evidence-based approach for helping a loved one engage with treatment that avoids both enabling and destructive confrontation
  • Attend Al-Anon or Nar-Anon — peer support specifically for family members
  • Set boundaries with compassion — limiting enabling behaviors while maintaining connection
  • Support their own wellbeing — sustainable family support for an SUD loved one requires the family member’s own stability

What family members can’t do: “fix” the patient through willpower or love alone. SUD requires the patient’s own engagement with treatment. Family support is meaningful; it is not substitute for clinical treatment.

Recovery capital — the resources that support sustained recovery

Recovery capital is a framework increasingly used in addiction research and practice to describe the personal, social, and community resources that support sustained recovery. Categories:

Personal recovery capital — individual-level resources:

  • Physical and mental health
  • Skills, education, employment capacity
  • Financial stability
  • Self-efficacy and recovery skills

Social recovery capital — relational resources:

  • Supportive family relationships
  • Recovery peers and sponsors
  • Friendship networks not centered on substance use
  • Employment and professional relationships

Community recovery capital — environmental resources:

  • Stable housing
  • Access to treatment and peer support in geography
  • Community-level attitudes toward recovery (non-stigmatizing)
  • Access to meaningful work, education, leisure activities

Higher recovery capital correlates with better outcomes. Individuals entering treatment with limited recovery capital (unhoused, financially insecure, thin social support, co-occurring health conditions) face more challenging recovery trajectories than individuals with robust recovery capital. This is not about deserving; it is about predicting what resources need rebuilding during treatment and continuing care.

Practical implication: effective treatment and continuing care build recovery capital alongside addressing substance use directly. Housing support, employment services, education access, family reconnection, and community integration are continuing-care components as important as clinical treatment for sustained recovery.

Treatment works — the evidence base

Evidence from decades of SUD treatment research supports treatment efficacy:

FDA-approved medications exist for opioid, alcohol, and nicotine use disorders. See opioid addiction, alcohol addiction, and benzodiazepine addiction pillars for medication-specific detail.

Evidence-based behavioral treatment modalities — CBT, Motivational Interviewing, Contingency Management, Mindfulness-Based Relapse Prevention, Seeking Safety, Dialectical Behavior Therapy — have extensive empirical support.

Integrated treatment for dual diagnosis outperforms parallel or sequential treatment. See dual diagnosis pillar.

Length of engagement matters: longer treatment correlates with better outcomes. See rehab timeline pillar.

Recovery support extends indefinitely: peer support, continuing-care clinical engagement, and family involvement sustain recovery over years.

Treatment outcomes are comparable to other chronic medical conditions. Research synthesizing SUD treatment outcomes against diabetes, hypertension, and asthma outcomes finds generally comparable treatment-response and relapse rates — meaning SUD treatment response is neither uniquely favorable nor uniquely unfavorable relative to other chronic conditions requiring long-term management.

Recovery as a process — the ROSC framework

Recovery Oriented System of Care (ROSC) — SAMHSA’s framework — treats recovery as a long-term process rather than a discrete endpoint. Key principles:

  • Recovery is individualized — the specific recovery pathway varies by person, substance, comorbid conditions, social context, and personal values
  • Recovery extends beyond clinical treatment — housing, employment, education, relationships, and community connection all support recovery
  • Peer support is integral — people in sustained recovery support people in earlier recovery stages
  • Recovery capital — the combination of personal, social, and community resources that support sustained recovery — matters as much as clinical intervention
  • Long-term, multiple pathways, patient-directed — not a single model prescribed by clinical authority

ROSC informs how California county behavioral health systems, DMC-ODS providers, and increasingly commercial treatment providers structure services. It frames recovery as sustainable over decades with appropriate support, rather than an acute medical intervention producing “cure.”

SoCal-specific context

Southern California’s SUD landscape has specific features discussed across our pillars:

  • Overdose mortality — California recorded 11,000+ overdose deaths in 2023; fentanyl involvement exceeds 70%. LA County alone exceeded 3,000 overdose deaths in 2022, the highest U.S. county count.
  • Fentanyl-era opioid treatment — buprenorphine and methadone access, Narcan availability under statewide standing order, harm reduction expansion
  • Medi-Cal DMC-ODS — zero-cost public coverage of the full ASAM continuum in all six SoCal counties
  • Dual diagnosis integration — California MHSA-funded Full Service Partnerships support integrated SMI + SUD care
  • Commercial insurance parity — SB 855 strengthens California state-regulated plans’ parity protection for SUD
  • Fraud-era enforcement history — Orange County’s 2015–2020 federal enforcement wave shaped the current verification-first regulatory environment
  • Regional treatment infrastructure — 1,501 DHCS-licensed SUD facilities across the six SoCal counties, with varying verification tiers

Understanding addiction for yourself or a family member?

Our editorial team can help you understand the clinical framework, discuss specific concerns about a substance or pattern, and direct you to appropriate evaluation and treatment pathways. We accept no referral fees from facilities. Calls are informational.

Contact our editorial team →

Use the Verify Insurance tool →

Need help now? Call (310) 596-1751. For immediate overdose crisis, call 911. For psychiatric crisis, call 988 (Suicide & Crisis Lifeline).

Last reviewed: 2026-04-23. Clinical framework references reflect DSM-5-TR, NIDA Principles of Drug Addiction Treatment, and SAMHSA published consensus at review date. Heritability estimates reflect published twin and family studies. This page is editorial content, not medical advice.

Looking for treatment options in your area? We can help point you in the right direction. (310) 596-1751 — or request a callback.